CHIR-265   Click here for help

GtoPdb Ligand ID: 5674

Synonyms: CHIR 265 | CHIR265 | RAF 265 | RAF-265 | RAF265
PDB Ligand
Compound class: Synthetic organic
Comment: CHIR-265 is an orally bioavailable inhibitor of RAF kinases, including the BRAF V600E mutant. It also inhibits phosphorylation of VEGFR2 [3] (link to this abstract at AACR Meeting Abstracts Online #4876).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 80.65
Molecular weight 518.13
XLogP 5.71
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2c1ccc(c2)Oc1ccnc(c1)c1[nH]cc(n1)C(F)(F)F
Isomeric SMILES Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2c1ccc(c2)Oc1ccnc(c1)c1[nH]cc(n1)C(F)(F)F
InChI InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)
InChI Key YABJJWZLRMPFSI-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A single Phase 2 clinical trial of CHIR-265 (a.k.a. RAF265) in metastatic melanoma (NCT00304525) has been completed. Development of this compound has not progressed beyond Phase 2.